Goldman Sachs
ANTH

Goldman Sachs’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Goldman Sachs’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-115,801
Closed -$37K – 6254
2018
Q1 		$37K Buy
+115,801
New +$173K ﹤0.01% 5556
2017
Q3 		– Sell
-42,692
Closed -$69K – 7027
2017
Q2 		$69K Sell
42,692
-2,306
-5% -$5.17K ﹤0.01% 6273
2017
Q1 		$153K Buy
44,998
+41,950
+1,376% +$198K ﹤0.01% 5866
2016
Q4 		$16K Sell
3,048
-344
-10% -$5.95K ﹤0.01% 6701
2016
Q3 		$85K Buy
3,392
+944
+39% +$23.8K ﹤0.01% 6308
2016
Q2 		$61K Buy
2,448
+389
+19% +$11K ﹤0.01% 6351
2016
Q1 		$60K Sell
2,059
-13,463
-87% -$365K ﹤0.01% 6344
2015
Q4 		$576K Buy
15,522
+10,818
+230% +$477K ﹤0.01% 4801
2015
Q3 		$229K Sell
4,704
-3,467
-42% -$242K ﹤0.01% 5884
2015
Q2 		$563K Buy
8,171
+5,839
+250% +$270K ﹤0.01% 5079
2015
Q1 		$83K Sell
2,332
-2,414
-51% -$71.4K ﹤0.01% 6509
2014
Q4 		$60K Buy
+4,746
New +$68.9K ﹤0.01% 6757

Other funds holding ANTH

WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Goldman Sachs's ANTH Position: Q2 2018 in Review

Goldman Sachs sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2018, closing a stake of 115,801 shares — an estimated $37K sold.

Goldman Sachs first reported a position in ANTH in Q4 2014 and held it in 12 quarters. The position peaked at $576K in Q4 2015. 5 funds tracked by Wall St. Rank hold ANTH as of Q2 2018.

  • Goldman Sachs reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Goldman Sachs sold 115,801 Anthera Pharmaceuticals, Inc. shares in Q2 2018, an estimated $37K.
  • Goldman Sachs first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2014 and held it in 12 quarters.
  • Goldman Sachs's Anthera Pharmaceuticals, Inc. position peaked at $576K in Q4 2015.
  • 5 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2018.

Based on Goldman Sachs's 13F filing for Q2 2018, filed 14 Aug 2018.